Stocktoria
PDS Biotechnology Corp PDSB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-01
PDS Biotechnology Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $19.0M | $22.6M | $27.8M | $29.4M | $11.3M |
| Operating income | -$31.5M | -$36.3M | -$43.0M | -$41.7M | -$21.4M |
| Interest expense | — | — | $4.2M | $1.3M | $0 |
| Income tax | -$1.2M | -$869,169 | -$1.4M | -$1.2M | -$4.5M |
| Net income | -$34.5M | -$37.6M | -$42.9M | -$40.9M | -$16.9M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 |
| Operating cash flow | -$27.8M | -$35.0M | -$33.6M | -$25.7M | -$12.5M |
| Free cash flow | -$27.8M | -$35.1M | -$33.6M | — | — |
| Cash & equivalents | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M |
| Total assets | $30.5M | $45.4M | $59.4M | $77.0M | $67.2M |
| Total liabilities | $21.2M | $26.4M | $33.3M | $33.0M | $4.0M |
| Shareholders' equity | $9.3M | $19.0M | $26.1M | $44.0M | $63.2M |
Source: SEC EDGAR filings · CIK 0001472091 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.